Sneha Saggurthi Joins Cartesian Therapeutics as Training Program Manager
July 11, 2024
| BioBuzz’s mission is simple: to be more connected. Our regionally-focused storytelling, programs, events and experiences connect, amplify and create impact across the life science workforce in growing biohubs. Submit your People On The Move (free and ongoing) to showcase your company’s growth by promoting your new hires and recent promotions. |
Sneha Saggurthi joins Cartesian Therapeutics as Training Program Manager. Saggurthi brings a wealth of experience in optimizing manufacturing processes, ensuring quality assurance, and developing effective training programs to drive operational success. Her contributions have made significant impacts across various organizations, touching all departments and ensuring training meets regulatory standards while optimizing performance.
Saggurthi emphasizes the importance of investment in training, highlighting that “it takes a village” to develop a strong, successful organization.
About Sneha Saggurthi
Sneha Saggurthi began her academic journey in pre-med at the University of Maryland, Baltimore County (UMBC), where she earned degrees in Psychology and Biology. This educational foundation led her to Catalent, where she began her career and steadily advanced through the ranks.
At Catalent, Sneha’s roles encompassed both commercial and clinical manufacturing. After transitioning to a full-time training role, she developed a renewed focus on training and operational excellence (OpEx). In addition to training, Sneha served as a Continuous Improvement (CI) Site Lead and was instrumental in preparing for audits, deviation remediation, and overseeing technical onboarding processes. Sneha’s cross-functional experience influences her unique approach to training, which incorporates OpEx tools into project management and deployment.
Sneha is a proud member of Women in Bio’s Capital Region chapter and was recently the speaker for the organization’s June Career MAPS Lunch and Learn where she discussed building a strong GxP Training Program.
In her current role at Cartesian Therapeutics, Sneha is passionate about setting people up for success. She plans to build comprehensive training programs that emphasize proactive training. Her work impacts all departments, ensuring that training meets regulatory standards and optimizes performance across the board.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. Cartesian Therapeutics, Inc. has recently secured $130 million in PIPE financing and dosed the first patient in its Phase 2 trial for Descartes-08, an mRNA cell therapy for systemic lupus erythematosus.
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
